Hailey Gilmore

We Will Call It Pala A Story For The Psychedelic Movement

Dropping in to remind you that this story exists, and it's already 5 years old.
"What vision do you hold in your heart for a psychedelic future?
What will you do now, while you can, to see that it is realized?"

#38 Hailey Gilmore: The Complexity of Psychedelic Science Welcome back to The Trip Report Podcast, a production of Beckley Waves.

Great 2 see both #APA s entering the #psychedelic chat. All hands welcome! Beyond funding, quality trials, & meaningful data, there are policy, process, & infrastructure to build 4 PAT coverage, access, & rollout, if approved. I recently spoke w/ Zach over at #TheTripReport abt these complexities:

Florida Man strikes again

Enjoyed this!

My 2023 reads (not pictured: Cloud Cuckoo Land (audio) on my 2nd Xcountry move of the year & the dozens of academic papers we all do for work). 2024 goal: more fiction! And - 1 book/month, so a 25% ⬆️. I used to have multiple going at a time, hoping focusing on 1 will help completion rate #tsundoku

Plant Parenthood Plant Parenthood is an online and in-person community of parents who use psychedelics, plant medicine and cannabis.

@gillbedi.bsky.social or www.plantph.com who i'm not sure is on blue sky yet?

I'm YEARS behind on all things TV, so I'll take all the recos!

1. Masters level epi/biostat & veteran clin ops mgr from the HIV treatment/prevention space using skillset to ⬆️rigor & reach of psychedelic trials-formerly at Lykos (IIT program, MSL), now consultant

2. Sorry-under NDA :) but here: luminousrcs.com

3. Finally watching "What we do in the shadows"!

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revoluti

Cybin Shares Positive 12-month Ph 2 Data for its Deiterated Psilocin Candidate, CYB003, in Major Depressive Disorder (MDD)

100% of patients responders and 71% in remission at the 12-month mark.

www.businesswire.com/news/home/20...